Brief: Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating A Safe And Well-Tolerated Profile
06/12/2021 12:38
Dec 6 (Reuters) - Bolt Biotherapeutics Inc BOLT.O :
* BOLT BIOTHERAPEUTICS REPORTS INTERIM BDC-1001 PHASE 1/2
DATA
DEMONSTRATING A SAFE AND WELL-TOLERATED PROFILE AND EMERGING
CLINICAL ACTIVITY AT THE ESMO IMMUNO-ONCOLOGY CONGRESS 2021
* BOLT BIOTHERAPEUTICS INC - COMPANY TO CONTINUE MONOTHERAPY
DOSE-ESCALATION AND EVALUATE WEEKLY DOSE REGIMEN
* BOLT BIOTHERAPEUTICS INC - COMBINATION DOSE-ESCALATION
STUDY OF
BDC-1001 WITH OPDIVO® ON TARGET TO INITIATE BY YEAR END 2021
Source text for Eikon: ID:nGNXc86KRm
Further company coverage: BOLT.O
((Reuters.Briefs@thomsonreuters.com;))